Clinical Trials Arena on MSN
Immuneering progresses MAPK inhibitor in lung and pancreatic cancer
The biotech will now take atebimetinib to mid- and late-stage trials in NSCLC and pancreatic cancer, respectively.
Mitogen-Activated Protein Kinase (MAPK) signalling cascades are fundamental to the regulation of numerous cellular processes, including stress response, inflammation, cell cycle control and apoptosis.
NOTE. P < .00357 represents statistical significance after the Bonferroni correction. Abbreviations: MAPK, mitogen-activated protein kinase; NA, unable to be calculated; NR, not reached; OS, overall ...
The FDA-approved drug combination specifically targets low-grade serous ovarian cancer, which primarily affects younger women ...
Laboratory studies suggest cinnamon’s bioactive compounds can alter key cancer-related signaling pathways, but researchers caution that human trials are essential before any preventive or therapeutic ...
The data on fibrolamellar carcinoma (FLC) is daunting, to say the least. Symptoms of this rare liver cancer, if they appear at all, are vague, and there are no biomarkers or blood tests to flag it at ...
CDK 4/6 inhibitors (CDK4/6i) remain part of the standard first-line treatment for patients with hormone receptor–positive metastatic breast cancer, offering demonstrable improvements in both ...
Researchers have discovered how a particular protein affects the growth and spread of colon cancer in humans. The study not only improves our understanding of why this type of cancer can be aggressive ...
Mitogen-Activated Protein Kinase (MAPK) signalling pathways represent a fundamental means by which cells translate extracellular stimuli into a wide array of intracellular responses, including ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results